Compare · MLYS vs NVO
MLYS vs NVO
Side-by-side comparison of Mineralys Therapeutics Inc. (MLYS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MLYS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 98.0x MLYS ($2.20B).
- Over the past year, MLYS is up 96.4% and NVO is down 29.3% - MLYS leads by 125.7 points.
- MLYS has been more active in the news (12 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for MLYS).
- Company
- Mineralys Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $26.73-0.98%
- $48.78+1.22%
- Market cap
- $2.20B
- $215.95B
- 1M return
- +3.69%
- +2.89%
- 1Y return
- +96.40%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2023
- News (4w)
- 12
- 4
- Recent ratings
- 10
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MLYS
- Chief Commercial Officer Warren Eric exercised 7,438 shares at a strike of $13.24 and sold $199,885 worth of shares (7,438 units at $26.87) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Chief Medical Officer Rodman David Malcom sold $11,036 worth of shares (416 units at $26.53) as part of a pre-agreed trading plan and exercised 416 shares at a strike of $15.44 (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Chief Executive Officer Congleton Jon sold $291,441 worth of shares (10,700 units at $27.24) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 603,621 units (SEC Form 4)
- Chief Medical Officer Rodman David Malcom exercised 14,058 shares at a strike of $7.28 and sold $556,671 worth of shares (20,407 units at $27.28) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 51,384 units (SEC Form 4)
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- Amendment: SEC Form 144/A filed by Mineralys Therapeutics Inc.
- SEC Form 144 filed by Mineralys Therapeutics Inc.
- SEC Form 144 filed by Mineralys Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S